Juvenile Idiopathic Arthritis (JIA) is the most prevalent pediatric rheumatologic illness. Forty percent of children with JIA have polyarthritis (poly-JIA), which is associated with persistently active disease characterized by synovitis, joint damage, decreased physical functional ability, and a progressive decrease in quality of life. Recent studies in adult rheumatoid arthritis suggest there exists a """"""""window of opportunity"""""""" very early in the disease course during which aggressive therapeutic approaches result in profound alteration of disease progression. This clinical trial seeks to determine if aggressive treatment initiated within 6 months of the onset of poly-JIA is capable of inducing a state of inactive disease (ID) within 6 months of initiation and later clinical remission on medication (CRM). METHODOLOGY: This proposal is a randomized, multi-center, prospective clinical trial up to 1 year in duration. A placebo-controlled double-blind phase of up to 6 months represents the pivotal portion of the trial. 86 children aged 2-17 years with poly-JIA of recent onset will be randomized to 1 of 2 aggressive treatment regimens: Arm A = Methotrexate (MTX;0.5 mg/kg/wk;max 40 mg/wk SQ) + dummy etanercept SQ weekly + dummy daily oral prednisone;Arm B = MTX (as in Arm A) + etanercept (0.8 mg/kg/wk SQ, max 50 mg/wk) + prednisone (0.5 mg/kg/d;max dose of 60 mg/d tapered to zero by 17 weeks). Subjects who achieve ID by or at the 6 month visit will continue treatment for an additional 6 months to determine if CRM is achieved. Those patients who do not achieve an ACR Pediatric 70 response by 4 months, or ID by 6 months will be offered open label Treatment Arm B. The primary analyses will compare the proportions of subjects in each treatment arm that achieve ID by 6 months and the safety profiles of the treatment groups. Secondary analyses will determine time to achieve ID, the proportion of subjects that attain CRM and the effect of CRM on physical functional ability and health related quality of life. MRI with IV gadolinium will be performed at baseline and at 6 months on 1 knee of 30 subjects (15 each from Arm A and B) to observe biologic correlates of active and inactive disease. SIGNIFICANCE: If a therapeutic strategy for poly-JRA can be identified that increases the likelihood of disease quiescence early in the disease course, much of the associated morbidity, decreased quality of life, and health care costs associated with this illness likely can be avoided.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
3R01AR049762-04S1
Application #
7932449
Study Section
Special Emphasis Panel (ZAR1-YZW-H (M2))
Program Officer
Witter, James
Project Start
2009-09-23
Project End
2011-09-22
Budget Start
2009-09-23
Budget End
2011-09-22
Support Year
4
Fiscal Year
2009
Total Cost
$193,417
Indirect Cost
Name
Seattle Children's Hospital
Department
Type
DUNS #
048682157
City
Seattle
State
WA
Country
United States
Zip Code
98105
Jiang, Kaiyu; Wong, Laiping; Sawle, Ashley D et al. (2016) Whole blood expression profiling from the TREAT trial: insights for the pathogenesis of polyarticular juvenile idiopathic arthritis. Arthritis Res Ther 18:157
Du, Nan; Jiang, Kaiyu; Sawle, Ashley D et al. (2015) Dynamic tracking of functional gene modules in treated juvenile idiopathic arthritis. Genome Med 7:109
Jiang, Kaiyu; Sawle, Ashley D; Frank, M Barton et al. (2014) Whole blood gene expression profiling predicts therapeutic response at six months in patients with polyarticular juvenile idiopathic arthritis. Arthritis Rheumatol 66:1363-71
Wallace, Carol A; Ringold, Sarah; Bohnsack, John et al. (2014) Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. J Rheumatol 41:2459-65
Wallace, Carol A; Giannini, Edward H; Spalding, Steven J et al. (2014) Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol 41:1163-70
Prahalad, Sampath; Conneely, Karen N; Jiang, Yunxuan et al. (2013) Susceptibility to childhood-onset rheumatoid arthritis: investigation of a weighted genetic risk score that integrates cumulative effects of variants at five genetic loci. Arthritis Rheum 65:1663-7
Prahalad, Sampath; Thompson, Susan D; Conneely, Karen N et al. (2012) Hierarchy of risk of childhood-onset rheumatoid arthritis conferred by HLA-DRB1 alleles encoding the shared epitope. Arthritis Rheum 64:925-30
Wallace, Carol A; Giannini, Edward H; Spalding, Steven J et al. (2012) Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 64:2012-21